Literature DB >> 77901

Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by alpha-amino acid esters of phenethyl alcohols.

U H Lindberg, S O Thorberg, S Bengtsson, A L Renyi, S B Ross, S O Ogren.   

Abstract

A series of alpha-amino acid esters of substituted phenethyl alcohols was prepared and tested as inhibitors of the neuronal reuptake of noradrenaline and 5-hydroxytryptamine. Some of the compounds are potent and very selective in blocking the 5-hydroxytryptamine uptake, as evidenced by biochemical data and behavioral tests. The most promising agent, alaproclate [2-(4-chlorophenyl)-1,1-dimethylethyl 2-aminopropanoate hydrochloride (I, IV)], was selected for further studies as a potential antidepressant agent. A discussion on structure--activity relationships (SAR) is given. In an attempt to explain the selective action on the mechanism of 5-hydroxytryptamine uptake by the new inhibitors, their structures are compared with those of the two neurotransmitters. From the tentative pharmacophore and conformations of transmitter (5-HT) and inhibitor (alaproclate) derived from SAR, a hypothetic carrier site for 5-HT uptake is deduced in terms of geometry and electronic properties.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 77901     DOI: 10.1021/jm00203a008

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  Potentiation of DOI-induced forward locomotion in rats by (-)-pindolol pretreatment.

Authors:  P Kaur; S Ahlenius
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Similar effect on REM sleep but differential effect on slow wave sleep of the two 5-HT uptake inhibitors zimeldine and alaproclate in cats and rats.

Authors:  L Sommerfelt; E R Hauge; R Ursin
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  The effects of alaproclate on the pupillary responses to tyramine, phenylephrine and pilocarpine in depressed patients.

Authors:  C Thompson; S A Checkley
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Effects of a single oral dose of 3-cyano-imipramine on serotonin uptake and content of platelets in healthy volunteers.

Authors:  M Kenny; T J Lenehan; R Lambe; A Darragh; I Brick; L M Omer
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Counteraction of the rapid tolerance to 8-OH-DPAT-induced corticosterone secretion in rats by activation of the GABAA receptor-chloride channel complex.

Authors:  D Kelder; S B Ross
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

6.  Alaproclate--an open clinical study in depressive illness.

Authors:  S J Frost; D Eccleston; E F Marshall; F Hassanyeh
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Effect of destruction of central noradrenergic and serotonergic nerve terminals by systemic neurotoxins on the long-term effects of antidepressants on beta-adrenoceptors and 5-HT2 binding sites in the rat cerebral cortex.

Authors:  H Hall; S B Ross; M Sällemark
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

8.  The effect of acute zimeldine and alaproclate administration on the acquisition of two-way active avoidance: comparison with other antidepressant agents, test of selectivity and sub-chronic studies.

Authors:  T Archer; S O Ogren; G Johansson; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats.

Authors:  Katherine L Nicholson; Robert L Balster
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530

10.  Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type.

Authors:  I Bergman; G Bråne; C G Gottfries; K G Jostell; I Karlsson; L Svennerholm
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.